Adalimumab (Humira)
Title: Adalimumab (Humira)Category: MedicationsCreated: 10/16/2018 12:00:00 AMLast Editorial Review: 10/16/2018 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - October 16, 2018 Category: Drugs & Pharmacology Source Type: news
Amgen Launches AMGEVITA ™ (Biosimilar Adalimumab) In Markets Across Europe
First Inflammation Biosimilar From Amgen's Portfolio to Launch in Europe
THOUSAND OAKS, Calif., Oct. 15, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that AMGEVITATM, a biosimilar to adalimumab, will launch in markets across Europe beginning on Oct. 16, 2018. AMGEVITA is the first adalimumab biosimilar to be approved by the European Commission (EC). AMGEVITA is authorized for the treatment of inflammatory diseases in adults, including moderate-to-severe rheumatoid arthritis; psoriatic arthritis; severe active ankylosing spondylitis (AS); severe axial spondyloarthritis without radiographic evidence of AS;...
Source: Amgen News Release - October 16, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
‘Patients Deserve to Know’: Trump Administration Wants Drug Commercials to Show Prices
TRENTON, N.J. — The federal government said Monday that it wants to force drugmakers to disclose prices for prescription medicines in their TV commercials.
The drug industry’s main trade group said drug companies are only willing to disclose the prices on their websites, not in commercials, and they’ll start doing that next spring.
Health and Human Services Secretary Alex Azar unveiled a proposal that would apply to all brand-name drugs covered by the Medicare and Medicaid programs, which is most medicines.
“Patients deserve to know what a given drug could cost when they’re being told about th...
Source: TIME: Health - October 16, 2018 Category: Consumer Health News Authors: LINDA A. JOHNSON / AP Tags: Uncategorized Healthcare onetime Source Type: news
Rivals line up to take on world’s best-selling drug
As the European patent on AbbVie’s Humira expires, biosimilars are ready to target $20bn market (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - October 14, 2018 Category: Pharmaceuticals Source Type: news
Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access
Sandoz, a Novartis division and the global leader in biosimilars, announced a global resolution of all intellectual property (IP) related litigation with AbbVie concerning the proposed Sandoz biosimilar Hyrimoz® (adalimumab)[1] for reference medicine Humira®* (adalimumab). (Source: World Pharma News)
Source: World Pharma News - October 12, 2018 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news
